Bristol-Myers Squibb Company (BRM.DE)
- Previous Close
42.04 - Open
42.06 - Bid 41.65 x 37000
- Ask 41.79 x 43000
- Day's Range
41.68 - 42.06 - 52 Week Range
41.68 - 64.10 - Volume
2,982 - Avg. Volume
2,534 - Market Cap (intraday)
84.496B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.90 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield 2.21 (5.26%)
- Ex-Dividend Date Apr 4, 2024
- 1y Target Est
--
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
www.bms.com34,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BRM.DE
Related Videos: BRM.DE
Performance Overview: BRM.DE
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BRM.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BRM.DE
Valuation Measures
Market Cap
84.68B
Enterprise Value
111.95B
Trailing P/E
--
Forward P/E
6.46
PEG Ratio (5yr expected)
2.08
Price/Sales (ttm)
2.03
Price/Book (mrq)
--
Enterprise Value/Revenue
2.49
Enterprise Value/EBITDA
5.78
Financial Highlights
Profitability and Income Statement
Profit Margin
-13.50%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
45.53B
Net Income Avi to Common (ttm)
-6.15B
Diluted EPS (ttm)
-2.90
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
140.82%
Levered Free Cash Flow (ttm)
--
Company Insights: BRM.DE
BRM.DE does not have Company Insights